Skip to main content
Premium Trial:

Request an Annual Quote

Abbott, GSK Collaborate on Lung Cancer Test

NEW YORK (GenomeWeb News) – Abbott said today that it will develop an automated molecular diagnostic PCR-based test that will be used to screen lung cancer tumors, under a collaboration with GlaxoSmithKline.

Abbott will develop a test for screening non-small cell lung cancer tumors for expression of the MAGE-A3 antigen, the presence of which is necessary to receive a GSK drug candidate that is being evaluated in a Phase III clinical study. Abbott has agreed to work with GSK to develop and commercialize a PCR test to detect the antigen using its m2000 automated instrument system.

"Through this partnership we aim to make MAGE-A3 testing of lung tumors available in standard pathology labs around the world," GSK's VP and Head of Immunotherapeutics, Vincent Brichard, said in a statement. "This means patients globally could be able to find out if they are eligible and can potentially benefit from targeted cancer treatment against this antigen, such as GSK's MAGE-A3 candidate ASCI."

Abbott noted that there currently aren't any nucleic acid-based tests approved by the US Food and Drug Administration for use in identifying patients who may benefit from non-small cell lung cancer therapies.

Financial and other terms of the alliance were not disclosed.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.